Magenta Therapeutics

OverviewSuggest Edit

Magenta’s mission is to revolutionize stem cell transplant as the treatment for immune and blood diseases. Stem cell transplant is a curative approach for a variety of severe blood cancers but is seldom used outside of cancer due to toxicities associated with the transplant procedure. Recent clinical data show that stem cell transplant can cure patients suffering from sickle cell disease, inherited metabolic disorders and severe autoimmune diseases. By developing safer and more effective therapeutics for conditioning, next generation products for stem cell mobilization and novel therapeutics for stem cell expansion, Magenta’s products will enable more patients to access the curative power of HSCT.
TypePublic
Founded2016
HQCambridge, MA, US
Websitemagentatx.com

Latest Updates

Employees (est.) (Dec 2019)72
Revenue (FY, 2019)$0
Share Price (Apr 2021)$13.2 (-1%)
Cybersecurity ratingAMore

Key People/Management at Magenta Therapeutics

Bastiano Sanna

Bastiano Sanna

COO
Michael Cooke

Michael Cooke

Chief Scientific Officer
Christina Isacson

Christina Isacson

VP and Head of Business Development
Jason Gardner

Jason Gardner

Chief Executive Officer, President and Cofounder
Show more

Magenta Therapeutics Office Locations

Magenta Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
100 Technology Square 5th floor
Show all (1)

Magenta Therapeutics Financials and Metrics

Magenta Therapeutics Revenue

USD

Net income (FY, 2020)

(74.9m)

EBIT (FY, 2020)

(78.7m)

Market capitalization (7-Apr-2021)

640.0m

Closing stock price (7-Apr-2021)

13.2

Cash (31-Dec-2020)

58.2m
Magenta Therapeutics's current market capitalization is $640 m.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

General and administrative expense

18.6m23.8m28.1m

R&D expense

41.3m59.2m50.6m

Operating expense total

60.0m83.0m78.7m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

General and administrative expense

4.3m5.3m5.8m5.9m6.1m7.3m7.4m6.6m

R&D expense

9.7m11.4m10.5m13.4m16.5m14.0m12.6m11.8m

Operating expense total

14.0m16.7m16.4m19.3m22.6m21.2m20.0m18.4m
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

58.3m65.1m58.2m

Prepaid Expenses

2.8m4.1m2.7m

Current Assets

145.3m149.8m151.5m

PP&E

10.2m9.9m8.3m
Quarterly
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(57.5m)(76.8m)(74.9m)

Depreciation and Amortization

875.0k1.8m2.0m

Accounts Payable

2.5m145.0k948.0k

Cash From Operating Activities

(41.9m)(57.1m)(64.0m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(24.8m)(40.8m)(14.8m)(32.5m)(53.5m)(20.0m)(39.1m)(56.8m)

Depreciation and Amortization

307.0k516.0k423.0k875.0k1.4m493.0k988.0k1.5m

Accounts Payable

995.0k2.1m(658.0k)(430.0k)(629.0k)1.1m(238.0k)(423.0k)

Cash From Operating Activities

(18.7m)(29.3m)(14.9m)(30.0m)(41.5m)(16.7m)(35.9m)(50.3m)
USDQ2, 2018

Financial Leverage

1 x
Show all financial metrics

Magenta Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Magenta Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Magenta Therapeutics Online and Social Media Presence

Embed Graph

Magenta Therapeutics News and Updates

Magenta Therapeutics Blogs

Magenta Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference

Magenta Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference Content Import Thu, 03/25/2021 - 08:02 Magenta Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference …

Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marrow Transplantation (EBMT) 2021 Annual Meeting

Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marrow Transplantation (EBMT) 2021 Annual Meeting Content Import Mon, 03/15/2021 - 08:01 Magen…

Magenta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

Magenta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference Content Import Tue, 03/09/2021 - 08:01 Magenta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference March 9, 2021 This release is a backfill from a Ne…

March 2021 Corporate Presentation

March 2021 Corporate Presentation Brian.Hoenig@n… Wed, 03/03/2021 - 08:01 March 2021 Corporate Presentation Display "add to calendar" true Event Type Conference Presentation Supporting Materials …

Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights

-- Magenta’s stem cell mobilization and targeted antibody-drug conjugate conditioning programs continue to advance, with four clinical trials ongoing or planned in 2021 – -- Ended year with approximately $148.8 million in cash, cash equivalents and marketable securities and maintains guidance that

Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning Program at Transplantation and Cellular Therapy (TCT) 2021 Annual Meeting

– Magenta will present a total of five abstracts, including four oral presentations, highlighting clinical and preclinical data across its portfolio – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 8, 2021-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel
Show more

Magenta Therapeutics Frequently Asked Questions

  • When was Magenta Therapeutics founded?

    Magenta Therapeutics was founded in 2016.

  • Who are Magenta Therapeutics key executives?

    Magenta Therapeutics's key executives are Bastiano Sanna, Michael Cooke and Christina Isacson.

  • How many employees does Magenta Therapeutics have?

    Magenta Therapeutics has 72 employees.

  • Who are Magenta Therapeutics competitors?

    Competitors of Magenta Therapeutics include The Biomedical Engineering Society, Althea and CSL.

  • Where is Magenta Therapeutics headquarters?

    Magenta Therapeutics headquarters is located at 100 Technology Square 5th floor, Cambridge.

  • Where are Magenta Therapeutics offices?

    Magenta Therapeutics has an office in Cambridge.

  • How many offices does Magenta Therapeutics have?

    Magenta Therapeutics has 1 office.